Loading...
Please wait, while we are loading the content...
Similar Documents
Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
| Content Provider | SAGE Publishing |
|---|---|
| Author | Savoy, J. Michael Welch, Mary Alma Nasnas, Patrice E. Kantarjian, Hagop Jabbour, Elias |
| Copyright Year | 2018 |
| Abstract | Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody–drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/2040620718812013?download=true |
| Starting Page | 347 |
| Ending Page | 356 |
| Page Count | 10 |
| ISSN | 20406207 |
| Issue Number | 12 |
| Volume Number | 9 |
| Journal | Therapeutic Advances in Hematology (TAH) |
| e-ISSN | 20406215 |
| DOI | 10.1177/2040620718812013 |
| Language | English |
| Publisher | Sage Publications UK |
| Publisher Date | 2018-11-22 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights Holder | © The Author(s), 2018 |
| Subject Keyword | Acute lymphoblastic leukemia monoclonal antibody inotuzumab |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology |
